歡迎來到演算法、軟體和硬體三位一體的未來世界論文書籍站
Vinblastine的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列懶人包和總整理
Vinblastine的問題，我們搜遍了碩博士論文和台灣出版的書籍，推薦Singh, Reetika,Sharma, Bechan寫的 Biotechnological Advances, Phytochemical Analysis and Ethnomedical Implications of Sapindus Species 可以從中找到所需的評價。
另外網站Vinblastine Sulfate | CAS 143-67-9 | SCBT也說明：Vinblastine Sulfate, CAS: 143-67-9, is an anti-mitotic agent which arrests the cell cycle in the G 2 /M-phase. Cited in 9 publications.
高雄醫學大學 醫學研究所博士班 蔡英美、江博暉、孫昭玲所指導 陳建旭的 程序性死亡配體1表現於上尿路泌尿上皮癌的角色 （2021），提出Vinblastine關鍵因素是什麼，來自於聯合陽性分數、Ki-67、程序性細胞死亡配體-1、根治性腎輸尿管切除術、上尿路泌尿上皮癌。
而第二篇論文國立臺灣大學 臨床醫學研究所 鄭安理、鄭文芳、郭頌鑫所指導 陳婉瑜的 放射治療與腫瘤免疫反應 （2021），提出因為有 放射治療、溶瘤病毒、腫瘤免疫的重點而找出了 Vinblastine的解答。
最後網站Vinblastine: View Uses, Side Effects and Medicines | 1mg則補充：Vinblastine is used in the treatment of Non-Hodgkin lymphoma (NHL), Breast cancer, Kidney cancer, Hodgkin's disease. View Vinblastine's uses ...
Biotechnological Advances, Phytochemical Analysis and Ethnomedical Implications of Sapindus Species
為了解決Vinblastine 的問題，作者Singh, Reetika,Sharma, Bechan 這樣論述：
Plants have always occupied a prominent position in the life of every living being. Plants are the primary source of food, shelter and medicines. The global inclination toward herbal medicine has advanced the expansion of plant-based pharmaceutical industries to a vast extent. The production of trad
itional medicine at global market has been estimated to touch US ＄5 trillion by 2050. Some of the useful plant-based drugs include vinblastine, vincristine, taxol, podophyllotoxin, camptothecin, digoxigenin, morphine, codeine, aspirin, atropine, capscicine, allicin, curcumin, artemesinin and ephedri
ne. Genus Sapindus is an important economical and medicinal trees, distributed over the world. Soap nuts contain higher amount of saponin, a natural detergent which can be used to clean clothes and hairs. Sapindus species possesses various pharmacological properties including antimicrobial, antioxid
ant, anti-inflammatory, anticancer, hepatoprotective, anti-trichomonas activity. Extracts of this plant are rich in various phytochemicals and polyphenolic compounds. All the pharmacological properties are due to presence of saponins. Biotechnological techniques can improve the saponin content; thus
this chemical content can be produced at large scale and can be used as phytomedicine. We hope that this book would be of great use to under graduates, postgraduates, scientists, researchers and faculty members who are studying, teaching or working in the field of Biotechnology, Phytochemistry and
Ethnopharmacology. The techniques explained in this book could be of immense use for the researchers working in this area. We shall deeply appreciate receiving any critical comments and suggestions from the readers from the different parts of globe which would help us improve the first edition of th
is publication. Dr. Reetika Singh, currently working as DST-SERB Scientist, has completed her PhD from Banaras Hindu University-Varanasi in Biotechnology. She has cleared several national level competitive exams like CSIR-JRF, ASRB-NET, GATE and secured higher rank. She was awarded with a prestigi
ous National-Post Doctoral Fellowship (N-PDF) of DST-SERB, New Delhi in 2016. She has visited China as Indian delegates in the 2nd BRICS Young Scientist Forum 2017. She has published six technical research papers and one review article in reputed International Journals with high impact factors. She
has also published eight book chapters in different edited book of various international publishers. She has attended several national and international symposia/ conferences and presented her research findings in many scientific meetings. She has been acting as a Reviewer and an Editor for couple o
f reputed international journals. She is also an active member of two reputed scientific societies in India.Dr. Bechan Sharma is presently working as a Professor and Ex-Head, Department of Biochemistry Allahabad University, Allahabad. He has completed his higher education such as B.Sc. (Honours)-198
0; M.Sc. (Biochemistry)-1982 and Ph.D. in Biochemistry (1988) from BHU-Varanasi. The areas of his research interest include Molecular Biology of HIV/AIDS, Tropical Diseases (Filariasis/Malaria), Drug design and development and Biochemical Toxicology. He has received number of Awards/ Honors and succ
essfully completed numerous important Academic/ Administrative Assignments. He has thirty years of teaching / research experience. He has carried out several research projects and published over 200 research papers including book chapters, molecular methods in peer reviewed International and Nationa
l Journals of repute. He has one US patent on HIV-1 genome structure based antiHIV-1 drugs design to his credit. He has supervised 18 PhDs and six PDFs. He is member/life member of several national/international scientific societies and attended numerous symposia/conferences in India and abroad. He
is Chief-Editor/Associate Editor/Executive Editor and Member Editorial Board of over 130 peer reviewed International and National Journals. He has been acting as honorary reviewer for over 150 International/National scientific journals. His 4 books have been published by International publishers and
2 are in print. He has worked as a visiting scientist in USA for over three years and visited different labs at Italy, France, Iran, Thailand, Hong Kong, Japan, Germany and Brazil to conduct different collaborative research projects related to Molecular Virology and Drug resistance. Prof. Sharma ha
s been awarded with ICMR’s Senior Scientist Fellowship 2014-15 in Biomedical Sciences under Indo-USA joint research programme to work at NIEHS-NIH, NC, USA with Prof. Samuel Wilson on DNA repair. Recently Prof. Sharma has been included as a member in World Virology Society-Sweden and in an Indo-Japa
nese research initiative towards eradication of HIV/AIDS in India. Prof. B. Sharma is a Fellow of Academy of Environmental Biology (AEB) and Bioved Research Society (BRS).
Vinblastine進入發燒排行的影片
程序性死亡配體1表現於上尿路泌尿上皮癌的角色
為了解決Vinblastine 的問題，作者陳建旭 這樣論述：
背景與研究重點：與西方國家相比，台灣上尿路泌尿上皮癌的發病率相對較高。根治性腎臟及輸尿管全切除術具有治癒器官局限性腫瘤疾病的潛力。然而，局部晚期或轉移性上尿路泌尿上皮癌的預後較差，需要用化學療法或免疫療法進行進一步的輔助或姑息治療以延長生存期。為了及早發現這些高風險的病人，尋找理想、可靠的生物標誌物對上尿路泌尿上皮癌進行預後評估或甚至治療效果評估具有重要意義。程序性死亡配體1 (programmed death-ligand 1, PD-L1) 對膀胱癌的影響已得到充分研究；然而，PD-L1在上尿路泌尿上皮癌中的角色仍不清楚。我們的研究由兩部分組成，第一部分是研究PD-L1對上尿路泌尿上皮癌
臨床結果和預後的影響。在第二部分中，我們嘗試結合其他生物標誌物（Ki-67）來評估在預測上尿路泌尿上皮癌預後中是否存在協同效應。方法：回顧性收集2013年至2018年在高雄長庚紀念醫院確診的上尿路泌尿上皮癌患者。我們僅納入接受根治性腎臟及輸尿管全切除術的患者，排除曾接受過手術前全身治療、診斷時已有轉移或有肌肉浸潤性膀胱癌病史的患者。我們使用Dako 22C3 pharmDx檢驗對全組織切片進行PD-L1免疫組織化學染色，並使用聯合陽性分數 (combined positive score, CPS)來計算PD-L1在腫瘤細胞及免疫細胞中的表現。PD-L1聯合陽性分數小於10定義為陰性表現。在第
二部分中，我們在同一研究族群中使用抗Ki-67抗體進行了Ki-67染色。 Ki-67指數≥20%被定義為過度表現。結果：第一部分共有105名患者符合研究條件而納入分析。在17.1%的上尿路泌尿上皮癌患者中發現PD-L1表現陽性(即CPS ≥ 10)。PD-L1聯合陽性分數≥ 10多見於術前腫瘤分期較高或診斷時已有淋巴結轉移的患者。在多變量分析中，PD-L1聯合陽性分數≥ 10和較高腫瘤期別獨立預測較差的癌症特異性存活期和總存活期。在第二部分中，由於有3名患者缺乏Ki-67染色，因此僅納入102名患者進行分析。在48%的上尿路泌尿上皮癌患者中觀察到Ki-67 ≥ 20%，Ki-67過度表現也與較
高腫瘤期別和不良的病理學特徵相關。在多變量分析中，將單獨的PD-L1、單獨的Ki-67以及PD-L1加上Ki-67的組合納入預測上尿路泌尿上皮癌預後因子的分析中。然而，PD-L1聯合陽性分數 ≥ 10和Ki-67 ≥ 20%的組合無法顯示出比單獨使用PD-L1有更好的癌症特異性存活期預測能力。結論：上尿路泌尿上皮癌患者PD-L1聯合陽性分數≥ 10 或 Ki-67 ≥ 20% 與較差的病理特徵相關。然而，只有PD-L1聯合陽性分數≥ 10是上尿路泌尿上皮癌預後的強預測因子。
放射治療與腫瘤免疫反應
為了解決Vinblastine 的問題，作者陳婉瑜 這樣論述：
本論文研究結合溶瘤病毒和放射線治療。放射治療是癌症治療的重要一環，而溶瘤病毒為癌症免疫治療的一個新方向。溶瘤病毒除了腫瘤消融之外，能促進腫瘤微環境的改變，增加免疫細胞浸潤。研究結合溶瘤病毒和放射線治療對於臨床應用有實際價值。本研究使用免疫健全老鼠模型，研究結合高劑量立體定位放射治療(SBRT)和溶瘤痘苗病毒(vaccinia virus)，探討此合併療法的抗腫瘤效果和免疫機轉。研究結果顯示合併高劑量立體定位放射治療和溶瘤痘苗病毒可增加動物體內抗腫瘤效果，增加脾臟之CD4+Ki-67+幫手T細胞和CD8+Ki-67+殺手T細胞。合併療法也會增加腫瘤內浸潤CD3+CD4+幫手T細胞和CD3+CD
8+殺手T細胞且降低調控T細胞(regulatory T cells)。並且，合併療法增強體外細胞死亡，部分經由細胞程序性壞死(necroptosis)而釋放出損害相關分子模式( damage-associated molecular patterns, DAMPs)，並改變巨噬細胞M1/M2的比例。此合併高劑量立體定位放射治療和溶瘤痘苗病毒的療法可做癌症臨床治療的參考。